ClinicalTrials.gg
CompletedNCT05497635Updated Apr 18, 2023

A Study of STSA-1002 in Healthy Subjects

A Phase 1 interventional study of STSA-1002 Injection and Placebo in Healthy Subject, sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd. Completed at 2 sites in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study is a Phase Ib, randomized, double-blind, placebo-controlled, multiple dose, dose escalation safety, tolerability,pharmacokinetic and pharmacodynamic study of STSA-1002 injection in healthy subjects. A total of 26 healthy subjects were enrolled in three dosage groups.

02

Conditions studied

  • Healthy Subject
03

In context

Lead sponsor

Staidson (Beijing) Biopharmaceuticals Co., Ltd is the lead sponsor of 28 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects, aged ≥ 18 but ≤ 45, male and female.
  • Weight:Male≥50.0kg,Female≥45kg;: 19.0-26.0 kg/m2, inclusive.
  • Medical history, vital signs, physical examination, laboratory examination (including blood routine, urine routine, blood biochemistry, coagulation function test, etc.) and all tests related to the test were normal or abnormal as determined by the researcher and had no clinical significance.
  • Subjects (including their partners) must take effective measures and have no birth plan or sperm or egg donation plan during the trial period and within 6 months after the end of the last administration.
  • Subjects are aware of the content, process and possible adverse reactions of the study and voluntarily signed the form(ICF).

Exclusion criteria

Exclusion Criteria:

  • History of tuberculosis; or combined with mixed lymphocyte culture + interferon assay results, chest imaging comprehensive evaluation of tuberculosis infection (if necessary, tuberculosis experts should be jointly evaluated).
  • Any clinically serious diseases such as respiratory, circulatory, digestive, urinary, blood, endocrine, neurological or mental disorder, or a history of the above diseases or any other diseases or physiological conditions that can interfere with the test results.
  • With any major surgical or surgical that possibly affects drug absorption, distribution, metabolism or excretion(Except appendicitis) within 2 months before screening or plan to undergo surgery during the study period.
  • Subjects with allergies or allergies to any components of the drug and its (such as allergies to two or more drugs, food, pollen), or the IgE is higher than the .
  • Positive screening test results for (HIV) antibodies, syphilis-specific antibody, surface antigen (HBsAg) or antibody (HCVAb).
  • Subjects with abnormal blood white blood cell count and during the screening period with clinical significance; or : male \<120g/L or female \<110g/L.
  • Drug abuse within 1 year before screening [such as morphine, ketamine (K powder), THC (marijuana), methamphetamine (ice), MDMA (ecstasy) ), cocaine, etc.]; or positive urine screening for drug abuse.
  • Subjects who have taken drugs that may affect immune function within 6 months before screening, have received any monoclonal antibody or biological agent for treatment (for any illness) within the previous 3 months, and have taken prescription drugs,non-prescription drugs,chinese herbal medicine within 14 days before screening.
  • Alcoholism within 6 months before screening (drinking more than 14 units of alcohol per week: 1 unit = 285mL of beer, or 25mL of spirits, or 100mL of wine) or unable to stop consuming any alcoholic products after enrollment until the entire study period or a positive alcohol breath test result.
  • Subjects who smoking (more than 5 cigarettes per day on average) within 3 months before screening or who could not stop using any tobacco products until the whole study period after enrollment.
  • Subjects who drink too much (more than 8 cups a day, 1 cup = 200 mL) of tea, coffee and other beverages rich in xanthine within 3 months before screening, or food or beverages that affect drug absorption, distribution, metabolism, and excretion.
  • Donation of blood or lost more than 400ml within 3 months before the first investigational product administration or plan to donate blood or blood components during the study period or within 3 months after the end of the study, or have a history of blood transfusion within 4 weeks before the first drug use of the study.
  • Subjects who participated in any unmarked drug, vaccine or medical device clinical trial within 3 months before screening and applied the drug, vaccine or medical device in the trial.
  • Vaccination within 14 days before the first dose or ready to be vaccinated during the study period to 2 months after the end of the study.
  • Subjects who have used long-acting estrogen or progestogen injections or implants within 6 months before the study or those who have used short-acting within 4 weeks before the study.
  • Female subjects who have had unprotected sex within 14 days prior to screening.
  • Blood β-HCG test positive or above the upper limit of the normal range (Female subjects).
  • Pregnant or lactating.
  • Any food or drink rich in xanthine (such as coffee, strong tea, chocolate, etc.) or food or drink that affects drug absorption, distribution, metabolism, and excretion within 48 hours before administration.
  • Unable to follow a unified diet (such as special requirements for diet, intolerance to standard meals, etc.).
  • Intolerance to venipuncturing blood collection, transfusion, or a history of blood and needle sickness.
  • Other circumstances in which the researcher considers it inappropriate to participate in the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    A low dose of group

    All subjects will be randomized to receive low dose of STSA-1002 or dose-matched placebo.

    Drug: STSA-1002 Injection · Drug: Placebo

  • Experimental
    A middle dose of group

    All subjects will be randomized to receive middle dose of STSA-1002 or dose-matched placebo.

    Drug: STSA-1002 Injection · Drug: Placebo

  • Experimental
    A high dose of group

    All subjects will be randomized to receive high dose of STSA-1002 or dose-matched placebo.

    Drug: STSA-1002 Injection · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events、Clinically Significant Laboratory Abnormalities、Clinically Significant Electrocardiogram、Vital Signs And Physical Examination Abnormalities.

    To evaluate the safety and tolerability of multiple intravenous administration of STSA-1002 in healthy adult subjects.

    Time frame: Up to Study Day 56

  2. Maximum plasma concentration (Cmax)

    To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

    Time frame: From Day 0 to Day 56

  3. Area under the plasma concentration-time curve from time 0 to the collection time point t of the last measurable concentration (AUC0-t)

    To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

    Time frame: From Day 0 to Day 56

  4. Area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)

    To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

    Time frame: From Day 0 to Day 56

  5. Time of maximum concentration (Tmax)

    To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

    Time frame: From Day 0 to Day 56

  6. Elimination half-life (t1/2)

    To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

    Time frame: From Day 0 to Day 56

  7. Mean residence time (MRT)

    To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

    Time frame: From Day 0 to Day 56

  8. Clearance (CL)

    To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

    Time frame: From Day 0 to Day 56

  9. Apparent volume of distribution (Vz)

    To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

    Time frame: From Day 0 to Day 56

  10. Maximum Concentration of the Analyte in Plasma at steady state(Cmax, ss)

    To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects

    Time frame: From Day 0 to Day 56

  11. Minimum Measured Concentration of the Analyte in Plasma at Steady State(Cmin, ss)

    To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects

    Time frame: From Day 0 to Day 56

  12. Time-averaged concentration at steady state(Cav, ss)

    To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects

    Time frame: From Day 0 to Day 56

  13. Area under the concentration curve from time 0 extrapolate to infinite time(AUCinf,ss)

    To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects

    Time frame: From Day 0 to Day 56

  14. Degree of fluctuation(DF)

    To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects

    Time frame: From Day 0 to Day 56

  15. Accumulation factor

    To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects

    Time frame: From Day 0 to Day 56

Secondary outcomes

  1. Change from baseline in concentration of free C5a and anti-drug antibody

    To evaluate the pharmacodynamics (PD) characteristics and immunogenicity of STSA-1002 in healthy subjects

    Time frame: From Day 0 to Day 56

  2. Change from baseline in concentration of Myeloperoxidase(MPO)、Neutrophil elastase(NE)、Proteinase3(PR3)、 C-X-C chemokine receptor 1(CXCR1)

    To evaluate the effect of STSA-1002 on MPO、NE、PR3、CXCR1

    Time frame: From Day 0 to Day 56

07

Study locations

2 sites
  • Beijing Shijitan Hospital, Capital Medical University
    Beijing, Beijing 102600, China
  • The Second Affiliated Hospital Of Xingtai Medical College
    Xingtai, Hebei 054000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Apr 2023, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2022
First posted
Aug 11, 2022
StartActual
Oct 14, 2022
Primary completionActual
Apr 6, 2023
CompletionActual
Apr 6, 2023
Last update
Apr 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05497635
Responsible party
Sponsor
First posted
Aug 11, 2022
Start date
Oct 14, 2022
Primary completion
Apr 6, 2023
Completion
Apr 6, 2023
Last update
Apr 18, 2023

Study contacts

Xinghe Wang, Ph.D
principal investigator · Beijing Shijitan Hospital, Capital Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Greziprubart

Start the discussion